SCHEMBL1987295

SCHEMBL1987295

Cc1cc(-c2ccncc2F)ccc1NC(=O)C1COc2ccccc2O1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.60
L3MBTL1 Q9Y468 2/20 0.60
RPS6KB1 P23443 1/20 0.57
ROCK2 O75116 3/20 0.54
AKT1 P31749 2/20 0.54
HPGD P15428 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
RAB9A P51151 5/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
POLB P06746 1/20 0.48
ALDH1A1 P00352 1/20 0.48
MAPT P10636 1/20 0.48
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
ROCK1 Q13464 1/20 0.48
HSD17B10 Q99714 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1992785 0.89 RPS6KB1 (0.55) NPC1L3MBTL1RPS6KB1ROCK2AKT1
SCHEMBL1989913 0.85 ROCK2 (0.71) NPC1L3MBTL1RPS6KB1ROCK2AKT1
SCHEMBL1989840 0.84 ROCK2 (0.72) NPC1L3MBTL1RPS6KB1ROCK2AKT1
SCHEMBL1989842 0.84 ROCK2 (0.72) NPC1L3MBTL1RPS6KB1ROCK2AKT1
SCHEMBL1988468 0.83 ROCK2 (0.61) NPC1L3MBTL1RPS6KB1ROCK2AKT1
SCHEMBL24324206 0.80 NPC1 (0.63) NPC1L3MBTL1RPS6KB1ROCK2AKT1
SCHEMBL12561684 0.80 ROCK2 (0.60) NPC1L3MBTL1RPS6KB1ROCK2AKT1
SCHEMBL1988754 0.79 RPS6KB1 (0.72) NPC1L3MBTL1RPS6KB1ROCK2AKT1
SCHEMBL1988756 0.79 RPS6KB1 (0.72) NPC1L3MBTL1RPS6KB1ROCK2AKT1
SCHEMBL1987650 0.78 ROCK2 (0.81) NPC1L3MBTL1RPS6KB1ROCK2AKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110150833-A1 BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2011-06-23 US disclosed
US-20110150833-A1 BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2011-06-23 US disclosed
US-20110150833-A1 BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2011-06-23 US disclosed
WO-2009079008-A1 BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS FENG YANGBO (US) 2009-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110150833-A1 BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS ROCK1, RHOA, RHOT2 NPC1 3662/4885L3MBTL1 3759/4885RPS6KB1 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.